Shares of CRISPR Therapeutics (CRSP) have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood disorders, much of these gains have pared mainly due to the waning interest of investors in CRSP.Despite securing the first product approval in Casgevy, the company is yet to record revenues from its sales. Also, a lack of pipeline updates beyond Casgevy’s approval is not sitting well with the investors.Anot ...